In both systems, considerably higher cytotoxicity was elicited against respective B7-H3-transfected tumour cells (Fig. 3b), suggesting that B7-H3 on tumour cells augments the cytolytic effector function of antigen-specific CD8+ T cells in vivo during this website the effector phase. We obtained five types of in vivo transplantable tumour cells including mastocytoma (P815), T lymphoma (EL4), plasmacytoma (J558L), squamous

cell carcinoma (SCCVII) and melanoma (B16) to investigate the effects of B7-H3 transduction on anti-tumour immunity. All tumour cells expressed endogenous cell surface B7-H3, although the levels were low (Fig. S1). Four tumours, but not the B16 melanoma, expressed substantial levels of MHC class I, but none of the tumours expressed endogenous CD80 or CD86. P815 and J558L cells expressed CD54. We established respective B7-H3 transfectants that stably expressed B7-H3 at high levels. B7-H3 transduction did not affect other cell-surface expression including MHC class

I, CD54, CD80 and CD86 (Fig. S1). All B7-H3-transduced tumour cell lines showed comparable growth in culture and the buy Dorsomorphin addition of anti-B7-H3 mAb did not clearly affect their growth (data not shown). Five B7-H3-transduced tumours and their respective parental tumours were injected subcutaneously into syngeneic mice, and tumour growth was monitored to examine tumorigenicity. All of the parental tumours grew progressively, whereas the growth of B7-H3-transduced

tumours was efficiently inhibited (Fig. 4). The inoculation of parental or B7-H3-transduced P815 cells into immunodeficient BALB/c nude mice showed a comparable growth curve (Fig. 4f), suggesting T-cell-dependent action in the rejection of B7-H3/P815 tumours. These results indicate that B7-H3 transduction into tumours markedly reduced tumorigenicity. To examine the requirements of CD8+ and G protein-coupled receptor kinase CD4+ T cells for tumour-associated B7-H3-induced anti-tumour immunity, we pre-treated with anti-CD4, anti-CD8 mAb, or a mixture of both mAbs to deplete CD4+, CD8+, or both T cells, and then B7-H3/SCCVII cells were inoculated. Depletion of either CD4+ or CD8+ T cells slightly enhanced mean tumour volume and four out of five mice failed to reject the tumours from CD4-depleted mice, whereas all of the mice failed to reject the tumours from CD8-depleted mice (Fig. 5a). The depletion of both CD4+ and CD8+ T cells dramatically promoted tumour growth, resulting in a reversal of the B7-H3 transduction effects. These results suggest that both CD4+ and CD8+ T cells are required, and that CD8+ T cells alone are insufficient for eradicating B7-H3/SCCVII tumours. We have recently reported that TLT-2 is a counter-receptor for B7-H3.